Beta Drugs Limited (NSE:BETA)
India
· Delayed Price · Currency is INR 1,098.00
+30.20 (2.83%)
At close: Mar 6, 2026
Beta Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 3,846 | 3,624 | 2,957 | 2,271 | 1,838 | 1,161 | Upgrade
|
| Revenue Growth (YoY) | 11.22% | 22.54% | 30.20% | 23.54% | 58.31% | 27.88% | Upgrade
|
| Cost of Revenue | 2,201 | 2,124 | 1,814 | 1,297 | 1,123 | 722.76 | Upgrade
|
| Gross Profit | 1,645 | 1,500 | 1,143 | 974.47 | 714.89 | 438.46 | Upgrade
|
| Selling, General & Admin | 470.43 | 380.45 | 276.67 | 242.78 | 169.97 | 121.32 | Upgrade
|
| Other Operating Expenses | 421.53 | 373.16 | 267.57 | 197.32 | 117.94 | 69.27 | Upgrade
|
| Operating Expenses | 1,051 | 878.75 | 642.06 | 544.2 | 360.45 | 259.33 | Upgrade
|
| Operating Income | 594.22 | 620.91 | 501.31 | 430.27 | 354.44 | 179.14 | Upgrade
|
| Interest Expense | -144.04 | -67.41 | -26.78 | -22.8 | -17.89 | -22.2 | Upgrade
|
| Interest & Investment Income | 51.1 | 51.1 | 10.84 | 6.63 | 4.52 | 3.34 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 0.84 | -3.09 | 0.43 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | 68.89 | 10.78 | 1.33 | -0.44 | 1.51 | -0.74 | Upgrade
|
| EBT Excluding Unusual Items | 570.18 | 615.38 | 487.54 | 410.57 | 343.01 | 159.54 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | -0.03 | Upgrade
|
| Other Unusual Items | -22.22 | -45.7 | - | - | - | - | Upgrade
|
| Pretax Income | 547.95 | 569.69 | 487.54 | 410.57 | 343.01 | 159.51 | Upgrade
|
| Income Tax Expense | 133.27 | 145.5 | 123.17 | 103.38 | 94.74 | 42.26 | Upgrade
|
| Net Income | 414.68 | 424.19 | 364.37 | 307.19 | 248.28 | 117.25 | Upgrade
|
| Net Income to Common | 414.68 | 424.19 | 364.37 | 307.19 | 248.28 | 117.25 | Upgrade
|
| Net Income Growth | -0.47% | 16.42% | 18.62% | 23.73% | 111.76% | 24.53% | Upgrade
|
| Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 | 10 | Upgrade
|
| Shares Change (YoY) | 10.48% | 5.00% | -4.76% | - | - | 1.39% | Upgrade
|
| EPS (Basic) | 39.54 | 42.02 | 37.90 | 30.43 | 24.60 | 11.61 | Upgrade
|
| EPS (Diluted) | 39.54 | 42.02 | 37.90 | 30.43 | 24.59 | 11.61 | Upgrade
|
| EPS Growth | -9.91% | 10.87% | 24.55% | 23.74% | 111.72% | 22.82% | Upgrade
|
| Free Cash Flow | - | -7.14 | 193.15 | 51.71 | 102 | 128.44 | Upgrade
|
| Free Cash Flow Per Share | - | -0.71 | 20.09 | 5.12 | 10.11 | 12.72 | Upgrade
|
| Gross Margin | 42.78% | 41.39% | 38.66% | 42.91% | 38.89% | 37.76% | Upgrade
|
| Operating Margin | 15.45% | 17.14% | 16.95% | 18.95% | 19.28% | 15.43% | Upgrade
|
| Profit Margin | 10.78% | 11.71% | 12.32% | 13.53% | 13.51% | 10.10% | Upgrade
|
| Free Cash Flow Margin | - | -0.20% | 6.53% | 2.28% | 5.55% | 11.06% | Upgrade
|
| EBITDA | 741.83 | 734.66 | 599.13 | 534.37 | 426.98 | 247.87 | Upgrade
|
| EBITDA Margin | 19.29% | 20.28% | 20.26% | 23.53% | 23.23% | 21.35% | Upgrade
|
| D&A For EBITDA | 147.61 | 113.75 | 97.82 | 104.1 | 72.54 | 68.74 | Upgrade
|
| EBIT | 594.22 | 620.91 | 501.31 | 430.27 | 354.44 | 179.14 | Upgrade
|
| EBIT Margin | 15.45% | 17.14% | 16.95% | 18.95% | 19.28% | 15.43% | Upgrade
|
| Effective Tax Rate | 24.32% | 25.54% | 25.26% | 25.18% | 27.62% | 26.50% | Upgrade
|
| Revenue as Reported | 3,969 | 3,688 | 2,971 | 2,279 | 1,846 | 1,166 | Upgrade
|
| Advertising Expenses | - | 35.6 | 14.57 | 12.57 | 8 | 6.74 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.